Novartis AG

Equities

Market Closed - Swiss Exchange Other stock markets 16:30:11 13/03/2026 GMT			5-day change	1st Jan Change
121.36 ^CHF	+0.43%		-1.54%	+10.73%

03-13	Novartis Announces FDA Approval for Cosentyx for Pediatric Patients with Moderate to Severe Hidradenitis Suppurativa	CI
03-13	Novartis Gets FDA Approval for Cosentyx in Pediatric Patients	MT

Published on 04/29/2025 at 04:20 pm BST - Modified on 04/29/2025 at 01:00 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning and good afternoon, and welcome to the Novartis Q1 2025 Results Release Conference Call and Live Webcast. [Operator Instructions] The

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

03-13	Novartis Announces FDA Approval for Cosentyx for Pediatric Patients with Moderate to Severe Hidradenitis Suppurativa	CI
03-13	Novartis Gets FDA Approval for Cosentyx in Pediatric Patients	MT
03-13	Novartis Cosentyx(R) receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa	DJ
03-12	Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research	RE
03-12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
03-12	Ipsen Announces Executive Changes	CI
03-10	Swiss stocks - Factors to watch on March 10	RE
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE
03-09	Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update	DJ
03-09	Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study	DJ
03-09	UBS keeps CEO's pay steady at $19 million as regulatory changes loom	RE
03-09	Berenberg Notes Novartis 'Fully Valued' After FY25 Report Review; Price Target Up	MT
03-09	UBS boss Ermotti's pay stays at $19.1 million in 2025	RE
03-06	Novartis Shareholders Approve Dividend Raise, Share Capital Reduction	MT
03-06	Novartis AG Approves Board and Committee Appointments	CI